Iambic Therapeutics vs Zocdoc

Side-by-side comparison of AI visibility scores, market position, and capabilities

Zocdoc leads in AI visibility (86 vs 56)
Iambic Therapeutics logo

Iambic Therapeutics

ChallengerHealthcare Tech

AI Drug Discovery

AI drug discovery biotech with $1.7B Takeda deal (Feb 2026). Lead drug IAM1363 (brain-penetrant HER2 inhibitor) in Phase 1. $100M+ raised (2025). Founded 2019, San Diego.

AI VisibilityBeta
Overall Score
C56
Category Rank
#160 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
60
Perplexity
58
Gemini
52

About

Iambic Therapeutics was founded in 2019 with the mission of applying AI-driven drug discovery to oncology — one of the most complex and high-value areas of pharmaceutical development. The company built proprietary machine learning models for structure-based drug design, training its systems on large datasets of protein-ligand interactions to accelerate hit identification, lead optimization, and candidate selection. This computational-first approach compresses timelines that traditionally require years of iterative chemistry work into months.\n\nIambic's lead asset, IAM1363, is a brain-penetrant HER2 inhibitor targeting HER2-mutated cancers including non-small cell lung cancer and breast cancer with brain metastases — a patient population with limited treatment options and high unmet need. The candidate entered Phase 1 clinical trials as a direct output of Iambic's AI design pipeline, validating the platform's ability to produce clinically viable molecules. The company's AI models are designed to simultaneously optimize for potency, selectivity, and the blood-brain barrier permeability that makes IAM1363 differentiated from approved HER2 inhibitors.\n\nIambic secured a $1.7B collaboration deal with Takeda in February 2026, one of the largest AI drug discovery partnerships in the industry's history, validating both the platform and its pipeline at the highest commercial level. The company raised over $100M in 2025 and has positioned itself alongside Recursion and Insilico Medicine as a leading AI-first biotech with clinical-stage proof points. The Takeda deal provides non-dilutive capital and development resources while preserving Iambic's pipeline optionality across multiple oncology indications.

Full profile
Zocdoc logo

Zocdoc

GrowthHealthTech

Patient Scheduling Marketplace

Zocdoc is a patient appointment booking marketplace that lets patients find and book in-network doctors in real time, with insurance verification and same-day availability filters.

AI VisibilityBeta
Overall Score
A86
Category Rank
#11 of 596
AI Consensus
70%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
80
Gemini
92

About

Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Patients can filter by specialty, insurance plan, location, and next available appointment, then book online in seconds — eliminating the phone-tag and hold-time historically required to schedule care. The platform verifies insurance acceptance in real time and sends automated reminders to reduce no-shows.

Full profile

AI Visibility Head-to-Head

56
Overall Score
86
#160
Category Rank
#11
79
AI Consensus
70
stable
Trend
stable
60
ChatGPT
88
58
Perplexity
80
52
Gemini
92
61
Claude
92
57
Grok
86

Key Details

Category
AI Drug Discovery
Patient Scheduling Marketplace
Tier
Challenger
Growth
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Iambic Therapeutics
AI Drug Discovery
Only Zocdoc
Patient Scheduling Marketplace

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.